VOR VS NVO Stock Comparison
Performance
VOR10/100
10/100
VOR returned -61.10% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.
NVO100/100
100/100
NVO returned 70.22% in the last 12 months. Based on SPY's performance of -13.73%, its performance is above average giving it a score of 100 of 100.
Technicals
VOR10/100
10/100
VOR receives a 10 of 100 based on 14 indicators. 0 are bullish, 12 are bearish.
NVO50/100
50/100
NVO receives a 50 of 100 based on 14 indicators. 6 are bullish, 6 are bearish.
Earnings
VOR10/100
10/100
VOR has missed earnings 6 times in the last 20 quarters.
NVO46/100
46/100
NVO has missed earnings 3 times in the last 20 quarters.
Profit
VOR10/100
10/100
Out of the last 16 quarters, VOR has had 0 profitable quarters and has increased their profits year over year on 0 of them.
NVO90/100
90/100
Out of the last 20 quarters, NVO has had 20 profitable quarters and has increased their profits year over year on 15 of them.
Volatility
VOR43/100
43/100
VOR has had a lower than average amount of volatility over the last 12 months giving it a score of 42 of 100.
NVO53/100
53/100
NVO has had a higher than average amount of volatility over the last 12 months giving it a score of 52 of 100.
Analyst Price Targets
VOR
"Analyst Price Targets" not found for VOR
NVO50/100
50/100
1 analysts offer 12-month price targets for NVO. Together, they have an average target of 0, the most optimistic target put NVO at 0 within 12-months and the most pessimistic has NVO at 0.
All score calculations are broken down here to help you make more informed investing decisions
Vor Biopharma Inc. Common Stock Summary
Nasdaq / VOR
Healthcare
Biotechnology
Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Novo-Nordisk A/S Summary
New York Stock Exchange / NVO
Healthcare
Biotechnology
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Compare Similar Companies
Compare VOR to other companies in the same or a similar industry.